02564na a2200229 4500
H12O
20180417112758.0
130622s2011 xxx||||| |||| 00| 0 eng d
H12O
eng
431
Grávalos Castro, Cristina
Oncología Médica
First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)
[artículo]
Critical Reviews in Oncology/Hematology,
2011.
77(1):78-84.
Formato Vancouver:
Sastre J, Aranda E, Grávalos C, Massutí B, Varella García M, Rivera F, et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol. 2011;77(1):78-84.
PMID: 20042346
Contiene 30 referencias
PURPOSE: to evaluate the efficacy and safety of first-line single-agent cetuximab in fit elderly patients with metastatic colorectal cancer, as well as potential molecular predictive factors for efficacy.
PATIENTS AND METHODS: patients aged 70 or older with metastatic CRC without criteria for frailty and no prior treatment for advanced disease were treated with single-agent cetuximab 400mg/m(2) followed by weekly 250mg/m(2) until disease progression or unacceptable toxicity.
RESULTS: forty-one patients were included. Two patients achieved a complete response and 4 patients had a partial response for an overall response rate of 14.6%. Fifteen patients (36.6%) remained stable. Median time to progression was 2.9 months and median overall survival 11.1 months despite two-third of patients received chemotherapy at progression. Forty-five percent of EGFR gene copy number positive patients by FISH were progression-free at 12 weeks, in contrast with 12% of FISH negative patients (p=0.04). Grade 3 skin toxicity was reported in 5 patients (12.2%). Hypersensitivity infusion reactions were not reported and there were no toxic deaths.
CONCLUSION: cetuximab is a safe monoclonal antibody with moderate activity in first-line metastatic colorectal cancer, but the present study does not support the use of cetuximab as single-agent in first-line fit elderly patients with metastatic CRC.
303
Servicio de Oncología Médica
http://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/9/pc9415.pdf
Solicitar documento
0
ddc
ART
9415
9415
0
0
ddc
0
0
H12O
H12O
2015-10-30
PC9415
2015-10-30
2015-10-30
ART